Your browser doesn't support javascript.
Omicron BA.1 breakthrough infection drives cross-variant neutralization and memory B cell formation against conserved epitopes.
Quandt, Jasmin; Muik, Alexander; Salisch, Nadine; Lui, Bonny Gaby; Lutz, Sebastian; Krüger, Kimberly; Wallisch, Ann-Kathrin; Adams-Quack, Petra; Bacher, Maren; Finlayson, Andrew; Ozhelvaci, Orkun; Vogler, Isabel; Grikscheit, Katharina; Hoehl, Sebastian; Goetsch, Udo; Ciesek, Sandra; Türeci, Özlem; Sahin, Ugur.
  • Quandt J; BioNTech, An der Goldgrube 12, 55131 Mainz, Germany.
  • Muik A; BioNTech, An der Goldgrube 12, 55131 Mainz, Germany.
  • Salisch N; BioNTech, An der Goldgrube 12, 55131 Mainz, Germany.
  • Lui BG; BioNTech, An der Goldgrube 12, 55131 Mainz, Germany.
  • Lutz S; BioNTech, An der Goldgrube 12, 55131 Mainz, Germany.
  • Krüger K; BioNTech, An der Goldgrube 12, 55131 Mainz, Germany.
  • Wallisch AK; BioNTech, An der Goldgrube 12, 55131 Mainz, Germany.
  • Adams-Quack P; BioNTech, An der Goldgrube 12, 55131 Mainz, Germany.
  • Bacher M; BioNTech, An der Goldgrube 12, 55131 Mainz, Germany.
  • Finlayson A; BioNTech, An der Goldgrube 12, 55131 Mainz, Germany.
  • Ozhelvaci O; BioNTech, An der Goldgrube 12, 55131 Mainz, Germany.
  • Vogler I; BioNTech, An der Goldgrube 12, 55131 Mainz, Germany.
  • Grikscheit K; Institute for Medical Virology, University Hospital, Goethe University Frankfurt, 60596 Frankfurt am Main, Germany.
  • Hoehl S; Institute for Medical Virology, University Hospital, Goethe University Frankfurt, 60596 Frankfurt am Main, Germany.
  • Goetsch U; Health Protection Authority, City of Frankfurt, 60313 Frankfurt am Main, Germany.
  • Ciesek S; Institute for Medical Virology, University Hospital, Goethe University Frankfurt, 60596 Frankfurt am Main, Germany.
  • Türeci Ö; DZIF-German Centre for Infection Research, External Partner Site, 60596 Frankfurt am Main, Germany.
  • Sahin U; BioNTech, An der Goldgrube 12, 55131 Mainz, Germany.
Sci Immunol ; 7(75): eabq2427, 2022 09 16.
Article in English | MEDLINE | ID: covidwho-1874491
ABSTRACT
Omicron is the evolutionarily most distinct severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant of concern (VOC) to date. We report that Omicron BA.1 breakthrough infection in BNT162b2-vaccinated individuals resulted in strong neutralizing activity against Omicron BA.1, BA.2, and previous SARS-CoV-2 VOCs but not against the Omicron sublineages BA.4 and BA.5. BA.1 breakthrough infection induced a robust recall response, primarily expanding memory B (BMEM) cells against epitopes shared broadly among variants, rather than inducing BA.1-specific B cells. The vaccination-imprinted BMEM cell pool had sufficient plasticity to be remodeled by heterologous SARS-CoV-2 spike glycoprotein exposure. Whereas selective amplification of BMEM cells recognizing shared epitopes allows for effective neutralization of most variants that evade previously established immunity, susceptibility to escape by variants that acquire alterations at hitherto conserved sites may be heightened.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Viral Envelope Proteins / COVID-19 Type of study: Randomized controlled trials Topics: Vaccines / Variants Limits: Humans Language: English Journal: Sci Immunol Year: 2022 Document Type: Article Affiliation country: Sciimmunol.abq2427

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Viral Envelope Proteins / COVID-19 Type of study: Randomized controlled trials Topics: Vaccines / Variants Limits: Humans Language: English Journal: Sci Immunol Year: 2022 Document Type: Article Affiliation country: Sciimmunol.abq2427